Merck will provide datasets for Isomorphic Labs’ artificial-intelligence-enabled drug-design engine. Isomorphic will deliver molecular designs produced by the system, according to the companies’ announcement on Thursday.
Merck will take responsibility for preclinical and clinical development, manufacturing and commercialization of any products arising from the work. “By combining Merck's substantial internal data capabilities and discovery expertise with Isomorphic Labs' powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster,” said George Addona, head of discovery for preclinical development and translational medicine at Merck Research Laboratories.
The financial terms include an undisclosed upfront payment from Merck to Isomorphic Labs. Isomorphic is also eligible for payments tied to specified research, development, regulatory and commercial milestones, plus tiered royalties on net sales. The agreement gives Isomorphic an option to co-fund development activities in exchange for elevated royalties.





Comments (0)
No comments yet. Be the first!